Citations

Clear

4207 citation(s) found for "Chen, Yu".

Improved Curvelet Transform-based Sparsity Promoting Algorithm for Fast Ultrasound Localization Microscopy
Trzasko, Joshua D. , Zhang, Jingke , Chen, Shigao , Zhang, Jingke , Lok, U‐Wai , Huang, Chengwu , DeRuiter, Ryan M.

Mayo Clinic

2024 IEEE Ultrasonics, Ferroelectrics, and Frequency Control Joint Symposium (UFFC-JS) | December 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-3

10.1109/uffc-js60046.2024.10794058 Get It

GPU-based Blockwise Non-Local Means Filtering with Microbubble Separation for 3D Ultrasound Localization Microscopy
Trzasko, Joshua D. , Zhang, Jingke , Chen, Shigao , Zhang, Jingke , Lok, U‐Wai , Huang, Chengwu , DeRuiter, Ryan M.

Mayo Clinic

2024 IEEE Ultrasonics, Ferroelectrics, and Frequency Control Joint Symposium (UFFC-JS) | December 18, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/uffc-js60046.2024.10794030 Get It

Advancements in Immunity and Dementia Research: Highlights from the 2023 AAIC Advancements: Immunity Conference
Kloske, Courtney M. , Batista, André F., Carrillo, María C. , Chakrabarty, Paramita , Chen, Xiaoying , Craft, Suzanne , Mesquita, Sandro Dá , Devanand, Davangere P. , Durán‐Laforet, Violeta , Fitzgerald‐Bocarsly, Patricia , Hong, Soyon , Jackvony, Stephanie , Lai, Laijun , Liddelow, Shane A. , Martín‐Peña, Alfonso , Orr, Anna G. , Quintana, Francisco José López , Ramey, G. , Sexton, Claire E. , Torrellas, Jose, Tsai, Andy P. , Wharton, Whitney , Da Mesquita, Sandro , Mahinrad, Simin , Barnum, Christopher J. , Bradshaw, Elizabeth M. , Butts, Brittany , Dabin, Luke Child , Elyaman, Wassim , Evans, Elizabeth E. , Foley, Kate E. , Harms, Ashley S. , Heneka, Michael T. , Huang, Yu‐Wen Alvin , Le Guen, Yann , Lemere, Cynthia Ann , Quintana, Francisco J., Rexach, Jessica E. , Rizzo, Stacey J. Sukoff , Tang, Alice , Olst, Lynn van , Walker, Keenan A. , Tansey, Malú G. , Wilcock, Donna M.

Mayo Clinic

Alzheimer's & Dementia | December 18, 2024 | Volume: 21 | Issue: 1 | Pages: No page available

10.1002/alz.14291 | PMID 39692624 Get It

Abstract The immune system is a key player in the onset and progression of neurodegenerative disorders. While brain resident immune cell‐mediated neuroinflammation and peripheral immune cell (eg, T cell) infiltration into the brain have been shown to significantly contribute to Alzheimer's disease (AD) pathology, the nature and extent of immune responses in the brain in the context of AD and related dementias (ADRD) remain unclear. Furthermore, the roles of the peripheral immune system in driving ADRD pathology remain incompletely elucidated. In March of 2023, the Alzheimer's Association convened the Alzheimer's Association International Conference (AAIC), Advancements: Immunity, to discuss the roles of the immune system in ADRD. A wide range of topics were discussed, such as animal models that replicate human pathology, immune‐related biomarkers and clinical trials, and lessons from other fields describing immune responses in neurodegeneration. This manuscript presents highlights from the conference and outlines avenues for future research on the roles of immunity in neurodegenerative disorders. Highlights The immune system plays a central role in the pathogenesis of Alzheimer's disease. The immune system exerts numerous effects throughout the brain on amyloid‐beta, tau, and other pathways. The 2023 AAIC, Advancements: Immunity, encouraged discussions and collaborations on understanding the role of the immune system.
A comprehensive benchmark study of methods for identifying significantly perturbed subnetworks in cancer
Yang, Le , Chen, Runpu , Goodison, Steve , Sun, Yijun

Mayo Clinic

Briefings in Bioinformatics | December 16, 2024 | Volume: 26 | Issue: 1 | Pages: No page available

10.1093/bib/bbae692 | PMID 39737568 Get It

Abstract Network-based methods utilize protein–protein interaction information to identify significantly perturbed subnetworks in cancer and to propose key molecular pathways. Numerous methods have been developed, but to date, a rigorous benchmark analysis to compare the performance of existing approaches is lacking. In this paper, we proposed a novel benchmarking framework using synthetic data and conducted a comprehensive analysis to investigate the ability of existing methods to detect target genes and subnetworks and to control false positives, and how they perform in the presence of topological biases at both gene and subnetwork levels. Our analysis revealed insights into algorithmic performance that were previously unattainable. Based on the results of the benchmark study, we presented a practical guide for users on how to select appropriate detection methods and protein–protein interaction networks for cancer pathway identification, and provided suggestions for future algorithm development.
Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric, Version 3.2024, NCCN Clinical Practice Guidelines In Oncology
Gupta, Samir , Axell, Lisen, Burke, Carol A. , Chen, Lee-may, Chung, Daniel C. , Clayback, Katherine M, Felder, Seth , Giardiello, Francis M., Gustafson, Susan, Hagemann, Andrea R. , Hall, Michael J. , Idos, Gregory , Joseph, Nora, Kassem, Nawal , Kelly, Kaitlyn, Kieber‐Emmons, AnnMarie, Kupfer, Sonia S., Lang, Katie, Llor, Xavier , Markowitz, Arnold J. , Prats, Mariana Moreno, Niell‐Swiller, Mariana, Pirzadeh‐Miller, Sara , Samadder, N. Jewel , Shibata, David , Swanson, Benjamin , Szymaniak, Brittany M. , Welborn, Jeanna, Wiesner, Georgia L. , Yurgelun, Matthew B. , Dwyer, Mary A., Darlow, Susan, Diwan, Zeenat, Samadder, Niloy Jewel, Gupta, Samir , Burke, Carol A , Hodan, Rachel , Weiss, Jennifer M. , Chung, Daniel C., Foda, Zachariah H. , Grady, William M. , Hampel, Heather , Katona, Bryson W , Outlaw, Darryl Alan , Stanich, Peter P.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | December 16, 2024 | Volume: 22 | Issue: 10 | Pages: 695-711

10.6004/jnccn.2024.0061 | PMID 39689429 Get It

Multigene panel testing has allowed for the detection of a growing number of inherited pathogenic/likely pathogenic variants in people at high risk of cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor syndrome, and Peutz-Jeghers syndrome. This manuscript provides the latest recommendations from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric on the screening and management of EC in patients at high risk for these syndromes, as well as the advantages and limitations of multigene panel testing. This manuscript also describes recent updates to these guidelines regarding de-implementation of colon cancer screening in individuals with CHEK2 pathogenic/likely pathogenic variants, based on the most up-to-date evidence regarding the association between CHEK2 pathogenic/likely pathogenic variants and colon cancer risk.
A self-attention-driven deep learning framework for inference of transcriptional gene regulatory networks
Zhong, Le, Chen, Zhuobin, Yu, Yanjia , Yu, Dan, Qin, Jing , Wang, Junwen , Yu, Dan , Qin, Jing , Wang, Junwen , Liu, Yong , Yan, Bin, Chen, Zhuobin

Mayo Clinic

Briefings in Bioinformatics | December 16, 2024 | Volume: 26 | Issue: 1 | Pages: No page available

10.1093/bib/bbae639 | PMID 39679439 Get It

Abstract The interactions between transcription factors (TFs) and the target genes could provide a basis for constructing gene regulatory networks (GRNs) for mechanistic understanding of various biological complex processes. From gene expression data, particularly single-cell transcriptomic data containing rich cell-to-cell variations, it is highly desirable to infer TF–gene interactions (TGIs) using deep learning technologies. Numerous models or software including deep learning–based algorithms have been designed to identify transcriptional regulatory relationships between TFs and the downstream genes. However, these methods do not significantly improve predictions of TGIs due to some limitations regarding constructing underlying interactive structures linking regulatory components. In this study, we introduce a deep learning framework, DeepTGI, that encodes gene expression profiles from single-cell and/or bulk transcriptomic data and predicts TGIs with high accuracy. Our approach could fuse the features extracted from Auto-encoder with self-attention mechanism and other networks and could transform multihead attention modules to define representative features. By comparing it with other models or methods, DeepTGI exhibits its superiority to identify more potential TGIs and to reconstruct the GRNs and, therefore, could provide broader perspectives for discovery of more biological meaningful TGIs and for understanding transcriptional gene regulatory mechanisms.
COL4A2 ‐Related Disorder Presenting in Adulthood With Rhabdomyolysis
Olarewaju, Bukola A., Tejon, Judy B, Shurrab, Shaymaa , Chen, Alicia , Shamoun, Fadi , Smith, Benn E., Osundiji, Mayowa A. , Tejon, Judy, Osundiji, Mayowa Azeez

Mayo Clinic

American Journal of Medical Genetics Part A | December 16, 2024 | Volume: 197 | Issue: 4 | Pages: No page available

10.1002/ajmg.a.63965 | PMID 39679724 Get It

ABSTRACT The alpha 1 and 2 chains of type IV collagen, encoded by the COL4A1 (MIM 120130) and COL4A2 (MIM 120090) respectively, play essential roles in the vascular basement membranes. Pathogenic variants in COL4A1 / COL4A2 are associated with autosomal dominant cerebral angiopathies. The clinical manifestations of COL4A1 / COL4A2 ‐related disorders include: aneurysms, intracerebral hemorrhage, polymicrogyria, porencephaly, heterotopia, periventricular leukomalacia, epilepsy, and neurodevelopmental disorders. COL4A1 pathogenic variants that are in exons 24 and 25 have been associated with hereditary angiopathy, nephropathy, aneurysms, and cramps. The multisystemic phenotypes of COL4A1 / COL4A2 ‐related disorders are increasingly being studied. Animal models have suggested that COL4A2 ‐related disorders may also manifest with a variable combination of multisystemic abnormalities affecting the eyes, muscles, and kidneys. Okano and colleagues recently reported a case of recurrent episodes of rhabdomyolysis in a 2‐year‐old with COL4A1 ‐related disorder raising fundamental questions on mechanisms of COL4A1 / COL4A2 variants in muscle homeostasis. To date, rhabdomyolysis has not been associated with COL4A2 ‐related disorder in humans. Rhabdomyolysis is a medical emergency, where there is elevated creatine kinase (CK) level in the blood and increased excretion of myoglobin in urine, due to skeletal muscle damage and release of intracytoplasmic proteins into systemic circulation. Rhabdomyolysis is a serious medical condition. It require intensive care management due to an increased risk of some life‐threatening complications [including disseminated intravascular coagulation, renal failure, and severe hyperkalemia]. Herein, we report a case of rhabdomyolysis in an adult with COL4A2 ‐related structural brain malformations (including polymicrogyria and heterotopia).
Pharmacogenetic and microRNA mechanisms of beta blocker use on bone
Lary, Christine W. , Atkinson, Elizabeth J. , Nayema, Zannatun, Roy, Tyler, Peters, Rebecca , Scott, Griffin T, Chen, Hongyu , Nagarajan, Archana , Brown, Aaron, Motyl, Katherine J. , Monroe, David G , Spillane, Jennifer, Scott, Griffin T, Brown, Aaron, Monroe, David G. , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | December 13, 2024 | Volume: 40 | Issue: 2 | Pages: 231-240

10.1093/jbmr/zjae200 | PMID 39673185 Get It

Abstract Motivated by studies showing an association between beta blocker (BB) use and positive bone outcomes, a pilot randomized control trial was performed at the Mayo Clinic which randomized postmenopausal women to placebo, propranolol (40 or 80 mg twice daily), atenolol (50 mg/d), or nebivolol (5 mg/d) to determine changes in bone turnover markers (BTMs) and in BMD over 20 wk. Pharmacogenetic effects and microRNA-mediated mechanisms involving beta adrenergic receptor and related genes have previously been found. We sought to validate these effects and discover new candidates in an ancillary study to the pilot clinical trial. We genotyped all participants and performed microRNA (miRNA) sequencing at baseline and at 20 wk for 24 participants from the atenolol or placebo groups. We discovered several variants in ADRB1, ADRB2, and HDAC4 which showed significant pharmacogenetic effects with BMD at multiple sites and with BTMs. Our miRNA results showed a significant treatment effect for miR-19a-3p over time with atenolol use in the low-responder group compared to placebo. Overall, the longitudinal miRNA analysis showed a large number of miRNAs which were up-regulated over the trial in the low responders but not the high responders compared to placebo, of which miR-19a-3p was one example. Finally, we compared the response to atenolol treatment for cardiovascular traits (pulse and blood pressure) with the response for the bone resorption marker, C-terminal telopeptide, and found a largely independent effect. Our results have implications for personalized therapy and for understanding mechanisms of BB treatment effect on bone.
Patient-Derived Xenograft-Guided Prediction of Chemotherapy Response in Triple-Negative Breast Cancer
Huang, Chen , Srinivasan, Ramakrishnan Rajaram , Lewis, Alaina , Sallas, Christina , Zhao, Na , Cao, Jin , Pilcher, Jacob B., Moon, Chang In, Liao, Yuxing , Rimawi, Mothaffar F. , Malovannaya, Anna , Li, Shunqiang , Kraushaar, Daniel C. , Goetz, Matthew P., Boughey, JC , Wang, Liewei, Kalari, Krishna R., Suman, Vera J., Damodaran, Senthil, Zheng, Xiaofeng, Meric-Bernstam, F, Welm, Bryan E. , Welm, Alana L. , Zhang, Bing , Lei, Jonathan T , Zhao, Na , Wen, Bo , Rimawi, Mothaffar , Lei, Jonathan T. , Dobrolecki, Lacey E. , Vasaikar, Suhas , Landua, John David , Pilcher, Jacob B. , Hilsenbeck, Susan Galloway , Ellis, Matthew J. , Petrosyan, Varduhi, Li, Kai shang , Saltzman, Alexander B. , Jain, Antrix , Wulf, Gerburg M. , Marangoni, Elisabetta , Wang, Tao , Goetz, Matthew P. , Damodaran, Senthil , Zheng, Xiaofeng , Meric‐Bernstam, Funda , Echeverria, Gloria Vittone , Anurag, Meenakshi , Chen, Xi , Lewis, Michael T.

Mayo Clinic

No container title available | December 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2024.12.09.627518 | PMID 39713418 Get It

Abstract Chemotherapy regimens for triple-negative breast cancer (TNBC) combine agents without knowing which agents drive response. Consequently, predictors derived from multi-agent regimens cannot be assumed to generalize to individual drugs or other regimens, motivating development of treatment-matched predictors. Here, we used TNBC patient-derived xenografts (PDXs) treated with carboplatin, docetaxel, or the combination to deconvolute drug-specific responses and identify associated molecular features. Combination treatment rarely improved upon the best single agent, with enhanced responses in only 13% of PDXs and antagonism in a comparable fraction. Proteogenomic analyses identified high cytokeratin-5 (KRT5) as a general marker of chemotherapy responsiveness and KRT5 immunohistochemistry discriminated responsive PDXs (AUROC, 0.83). To train treatment-specific predictors, we integrated these data with independent PDX and clinical cohorts with responses assessed after anthracycline-free platinum, taxane, or platinum-taxane therapy, ensuring response corresponded to the modeled treatment. Four feature selection strategies yielded largely nonoverlapping biomarker panels converging on treatment-relevant pathways. On independent test data, RNA-based predictors of complete response (CR) to platinum-based (carboplatin or cisplatin) and taxane-based (docetaxel or paclitaxel) chemotherapy achieved AUROCs of 0.80 and 0.86, respectively. For platinum-taxane regimens (carboplatin plus docetaxel or paclitaxel), proteomic-guided feature selection generated a 10-biomarker, protein- informed RNA predictor of pathologic complete response (pCR) that outperformed RNA-only feature selection and achieved an AUROC of 0.85 in an independent clinical cohort, while retaining practicality as an RNA-based assay. Treatment-matched integration of multi-omic PDX and clinical datasets provides a framework for chemotherapy-specific predictors with clinically relevant performance, supporting biomarker-guided precision selection and treatment optimization for patients with TNBC. Statement of significance Integration of multi-omic data from patient-derived xenografts with treatment-matched clinical cohorts yielded three retrospectively validated predictors of platinum, taxane, and platinum+taxane response, enabling biomarker-guided chemotherapy selection for patients with triple-negative breast cancer.